Kyverna Therapeutics
KYTX
121 hedge funds and large institutions have $335M invested in Kyverna Therapeutics in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 36 increasing their positions, 28 reducing their positions, and 21 closing their positions.
52% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 21
44% more call options, than puts
Call options by funds: $1.73M | Put options by funds: $1.2M
29% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 28
11% more capital invested
Capital invested by funds: $301M → $335M (+$34.2M)
9% more funds holding
Funds holding: 111 → 121 (+10)
4.24% more ownership
Funds ownership: 57.62% → 61.86% (+4.2%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$20M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.49M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$7.06M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.55M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.14M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$5.23M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.74M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.28M |
| 5 |
Millennium Management
New York
|
-$3.25M |
KYTX Hedge Fund Activity: Q2 2026 in Review
121 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q2 2026, worth a combined $335M — up 11% from $301M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new KYTX positions and 21 closed out — a net gain of 11 holders — while 36 added to existing stakes and 28 trimmed.
The largest buyer was BlackRock, adding an estimated $20M. The largest seller was Balyasny Asset Management, cutting an estimated $9.14M.
- 121 institutional investors held Kyverna Therapeutics (KYTX) as of Q2 2026, up from 111 in Q1 2026.
- Funds reported $335M of Kyverna Therapeutics stock for Q2 2026, up 11% quarter-over-quarter.
- 32 funds opened new Kyverna Therapeutics positions in Q2 2026 and 21 closed out, a net change of +11 holders.
- The largest Kyverna Therapeutics buyer in Q2 2026 was BlackRock, an estimated $20M added.
- The largest Kyverna Therapeutics seller in Q2 2026 was Balyasny Asset Management, an estimated $9.14M sold.
Based on aggregated 13F filings for Q2 2026.